UNSPSC 51141550: Carisbamate

This classification denotes an anticonvulsant agent with the molecular formula C9H10CLNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P7725I9V3Z. The term CARISBAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21, no. 3, 2007, list 58. ). As of Q4 2014, CARISBAMATE remains the US FDA Preferred Term for this commodity. Carisbamate bears US NLM identifiers UMLS ID C1871983 and NCI Concept Code C75161. SMILES: C1=CC=C(C(=C1)C(COC(=O)N)O)CL..

UNSPSC 51141550 Carisbamate is a Commodity code nominally tied to a specific anticonvulsant drug, but recent state and local opportunities show that issuing bodies are using this code to solicit a much broader set of pharmaceutical and health products — naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. The actual work involves competitive procurement of finished pharmaceuticals and related medical products for distribution through health and human services channels, with vendors supplying through authorized wholesaler networks, meeting cGMP and Drug Supply Chain Security Act compliance, and delivering products on fixed or negotiated net-pricing models. State and local buyers under this code include county health departments (Seminole County, Florida), state HHS commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple participating states including Oregon).

Geographic activity spans Florida, Texas, Minnesota, and Oregon, with recent procurement intensity in the Upper Midwest and South. Representative opportunities include Seminole County's competitive bid (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's Request for Information (HHS0017013, posted April 3, 2026) on direct-to-manufacturer prescription programs to inform future procurement strategy; and Minnesota's multistate RFP (S1070000015802, due March 26, 2026) for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with contract award and pricing effective July 1, 2026. Contracts typically require two years' minimum commitment with renewal options, comprehensive insurance including $5 million commercial general liability, and price evaluation weighted heavily toward cost competitiveness (75 percent in the Minnesota case). Vendors must maintain chargeback relationships with authorized wholesalers and demonstrate electronic data interchange capability for order and inventory management.